CRH Medical Corp. | StockChase
81
CRH Medical Corp. (CRH-T)

Last Price Recorded: $2.5200 on 2017-11-24

ON STOCKCHASE SINCE Jul 2009

biotechnology/pharmaceutical

CRH Medical Corp.


Signal Opinion Expert
     

2017-01-06

BUY
CRH Medical Corp. (CRH-T)

ROC on this is tremendous. He has it as 104%, which is almost unheard of. Also, it looks undervalued.

biotechnology/pharmaceutical
Matt Kacur

President, FSA Financial Science and Art

Price: $7.810
Owned: Unknown

2017-01-03

COMMENT
CRH Medical Corp. (CRH-T)

Technically, this looks fantastic. On any medical type stocks, you go with the wave. Right now the wave is up, and if he had to Buy or Sell it, he would buy.

biotechnology/pharmaceutical
Elliot Fishman

Director, US & International Equity Trading Portfolio Adviso

Price: $7.250
Owned: Unknown

2016-12-20

BUY
CRH Medical Corp. (CRH-T)

It is a buy or a hold.  He is one of the largest holders.  This has been a top pick of his.  It is a health care company, the top performing one in Canada this year.  They did a very good job at increasing their earnings.  Last quarter the stock took off.  A lot more small cap managers are looking at it now.  He likes the management team from a previous company.

biotechnology/pharmaceutical
Peter Imhof

Vice President & Portfolio Manager, AGF Investments Inc

Price: $7.060
Owned: Yes

2016-12-05

SELL
CRH Medical Corp. (CRH-T)

A good little Canadian medical story. Operates primarily in the US, and has been rolling up some healthcare services. He is cautious in this area right now. The US health business is pretty complicated right now, as there are a bunch of pieces to it, unlike the Canadian system. One segment of this company has a fair bit of “off network” business, which pays much better than being paid by Medicare and Medicaid, but sometimes it is hard to get paid, as insurers take their time. Companies like this could be under a bit of pressure next year, so he would be cautious. At this point he wouldn’t be owning it.

biotechnology/pharmaceutical
Alex Ruus

Portfolio Manager, Arrow Capital Management

Price: $7.530
Owned: No

2016-11-16

TOP PICK
CRH Medical Corp. (CRH-T)

This continues to grow by acquisition. They have 2 different product lines, but the anaesthesiology side is where they are really starting to grow. Generating between $5-$6 million in cash flow per quarter, along with a line that allows them to continue to make acquisitions. They’ve been pretty disciplined about how they have done this. (Analysts’ price target is $7.52.)

biotechnology/pharmaceutical
Bruce Campbell (2)

President & Portfolio Manager, Stone Castle Investment Management Inc.

Price: $7.390
Owned: Yes

2016-10-26

COMMENT
CRH Medical Corp. (CRH-T)

The company is not going to be out raising money, but are going to be doing smaller tuck in acquisitions. They are in the acquisition business. If they have the cash flow to fund an acquisition, they will be fine, but if not and it is something bigger, they’ll probably have to go to the market.

biotechnology/pharmaceutical
Bruce Campbell (2)

President & Portfolio Manager, Stone Castle Investment Management Inc.

Price: $6.210
Owned: Yes

2016-10-20

HOLD
CRH Medical Corp. (CRH-T)

This has spent the last 18 months consolidating, and has just recently broke out of a trading range at around the $5.40-$5.50 level. He sees a lot of upside in this. A very well-run company. Their cash ROE is north of 30%, and their cash P/E ratio is at around 10 or 11.

biotechnology/pharmaceutical
Jason Del Vicario

Portfolio Manager, HollisWealth

Price: $6.140
Owned: Yes

2016-09-29

HOLD
CRH Medical Corp. (CRH-T)

He really likes the management team.  He continues to hold it although the whole healthcare sector has been under scrutiny.  Their earnings have grown as they made tuck-in acquisitions.  They recently did some marketing.  Over the next couple of years earnings estimates should go up.

biotechnology/pharmaceutical
Peter Imhof

Vice President & Portfolio Manager, AGF Investments Inc

Price: $5.110
Owned: Yes

2016-09-21

COMMENT
CRH Medical Corp. (CRH-T)

They continue to execute. Did a big acquisition almost 2 years ago, and now are just doing smaller incremental acquisitions that continue to build out their business. He thinks the process will continue. This has bumped up a little in valuation, and as a result it dropped down in his ranking, so he recently sold his holdings. He wouldn’t be surprised if there was an equity issue from the company in the future.

biotechnology/pharmaceutical
Bruce Campbell (2)

President & Portfolio Manager, Stone Castle Investment Management Inc.

Price: $5.220
Owned: No

2016-09-06

BUY on WEAKNESS
CRH Medical Corp. (CRH-T)

A good, small-cap, Canadian health care stock. A teensy bit too expensive for him right now. He likes where the business is going. Would be a buyer at the bottom of the 52-week trading range. He likes management and the board. (See Top Picks.)

biotechnology/pharmaceutical
Alex Ruus

Portfolio Manager, Arrow Capital Management

Price: $4.750
Owned: No

2016-09-02

COMMENT
CRH Medical Corp. (CRH-T)

This is one of the stocks that gets bucketed into the healthcare rollup. Scores well on price momentum and on valuation. Has a good balance sheet and have been growing their earnings. However, they missed on their recent quarter. If looking to play some of these “growth by acquisition” stories, this would be the one to play.

biotechnology/pharmaceutical
Jason Mann

CIO & Co-Founder, Edgehill Patners

Price: $4.780
Owned: No

2016-08-19

COMMENT
CRH Medical Corp. (CRH-T)

They have a product that they have been marketing and selling for some time, and are taking the cash flow from that and putting it into acquiring anaesthesiology clinics in the US. Feels this is quite undervalued given their growth prospects. They are growing their bottom line by 30% a year. He likes this a lot.

biotechnology/pharmaceutical
Jason Del Vicario

Portfolio Manager, HollisWealth

Price: $4.750
Owned: Yes

2016-08-18

BUY
CRH Medical Corp. (CRH-T)

He likes this whole space on a secular basis.  You will have a wide disparity across the whole spectrum of stocks.  We found a breakout at the beginning of August.  There is support from the end of June.  It made a move when it was supposed to.  This stock has a nice trend.  It has been in a nice band since the beginning of last year.  There is some heavy duty volatility also.

biotechnology/pharmaceutical
Hap (Robert) Sneddon FCSI

Chief Portfolio Manager & Founder, Castlemoore Inc.

Price: $4.750
Owned: No

2016-07-20

PAST TOP PICK
CRH Medical Corp. (CRH-T)

(A Top Pick Sept 28/15. Up 23.28%.) Not sure who is buying this, but somebody is buying quite a bit of stock. Most healthcare stocks in Canada have not done well, but this one has. He really likes management, which underpromises and overdelivers. Recently made a few acquisitions which should be accretive. Only trading at about 8.5X EBITDA with very good growth over the next couple of years.

biotechnology/pharmaceutical
Peter Imhof

Vice President & Portfolio Manager, AGF Investments Inc

Price: $5.120
Owned: Yes

2016-06-30

TOP PICK
CRH Medical Corp. (CRH-T)

It has news out today.  They have a consistent growth business and an acquisition business.  They are making nice earnings growth.  They buy a business for half what the stock trades for.  They are slow and steady about it.  They expanded into the US.  Trading at a reasonable multiple.  A year from now they will have done more acquisitions.

biotechnology/pharmaceutical
Bruce Campbell (2)

President & Portfolio Manager, Stone Castle Investment Management Inc.

Price: $5.030
Owned: Yes

Showing 31 to 45 of 81 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.